Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Analysts have placed intismeran central to Moderna’s long-term growth beyond infectious diseases.
Read Full Article
Pharma Tech
ProBio signs global antibody licensing deal with AbTis
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Read Full Article
Express Pharma
How consumers’ demand for transparency will raise the scientific standard of dermocosmetics
Professor Dr. Gabriel Serrano, Founder, Sesderma shares insights on how global formulations may not always address the needs of Indian skin types, and why precision dermatology and delivery can address these gaps, in an email interaction with Viveka Roychowdhury The post How consumers’ demand for transparency will raise the scientific standard of dermocosmetics appeared first on Express Pharma.
Read Full Article
Pharma Tech
Democrat midterm landslide spells greater Trump oversight, marginal reforms Â
The US midterms will result in increased power for the Democrats, but experts don't foresee significant healthcare policy changes.
Read Full Article
Pharma Tech
Lilly-backed Oyster Therapeutics raises $60m for neurological degraders
Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Nov 11, 2026, 11:50 AM
Alzheon Initiates the P-III (ORION-E4) Trial of Valiltramiprosate (ALZ-801) for Alzheimer’s Disease
Shots: Alzheon has launched the P-III (ORION-E4) trial evaluating valiltramiprosate (ALZ-801; 265mg, BID) vs PBO for 78wks. in ~550 APOE4/4 homozygotes with MCI due to Alzheimer’s disease across ~150 sites in ~12 countries; 1EP: change in CDR-SB at Wk. 78 New P-III (APOLLOE4) analyses to be presented at CTAD 2026 showed 39% lower incidence of… The post Alzheon Initiates the P-III (ORION-E4) Trial of Valiltramiprosate (ALZ-801) for Alzheimer’s Disease appeared first on PharmaShots.
PharmaShots
Nov 11, 2026, 11:44 AM
Ascletis Submits IND Application to the US FDA for ASC30_39 FDC to Treat Obesity
Shots: Ascletis has submitted an IND application to the US FDA for ASC30_39 FDC, a once-daily oral FDC tablet of small molecule GLP-1R agonist ASC30 & selective amylin receptor agonist ASC39, for obesity In dogs, ASC30_39 FDC showed high oral bioavailability, high drug exposure & a half-life of up to 12hrs., consistent with the monotherapies;… The post Ascletis Submits IND Application to the US FDA for ASC30_39 FDC to Treat Obesity appeared first on PharmaShots.
PharmaShots
Nov 11, 2026, 11:34 AM
Lipocine Doses First Participant in P-III (BLOOM) Study of LPCN 1154 for Postpartum Depression
Shots: Lipocine has dosed the first participant in the placebo-controlled outpatient P-III (BLOOM) study evaluating LPCN 1154 (oral brexanolone) as a 48hrs. at-home treatment in ~120 pts with postpartum depression (PPD) The study will assess the same 48hrs. regimen & 1EP as the prior P-III trial, i.e., change from baseline in HAM-D17 total score at… The post Lipocine Doses First Participant in P-III (BLOOM) Study of LPCN 1154 for Postpartum Depression appeared first on PharmaShots.
Pharma Tech
Nov 11, 2026, 11:27 AM
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Analysts have placed intismeran central to Moderna’s long-term growth beyond infectious diseases.
PharmaShots
Nov 11, 2026, 11:21 AM
Nimbus Therapeutics Doses First Subjects in P-I Trial of NDI-225673 for Immune-Mediated Inflammatory Diseases
Shots: Nimbus Therapeutics has dosed the first subjects in the P-I trial evaluating NDI-225673 (oral, highly selective SIK2 inhibitor) as SAD & MAD in healthy volunteers, assessing safety, tolerability, PK & PD In preclinical studies, selective SIK2 inhibition suppressed TNFα, IL-6, IL-23 & IL-1β while increasing IL-10 & tissue-repair mediators (AREG, THBS1), and reduced disease… The post Nimbus Therapeutics Doses First Subjects in P-I Trial of NDI-225673 for Immune-Mediated Inflammatory Diseases appeared first on PharmaShots.
PharmaShots
Nov 11, 2026, 11:06 AM
Jubilant Therapeutics Reports Preliminary P-I Data of JBI-802 for Essential Thrombocythemia and Related MPNs
Shots: Jubilant Therapeutics has reported preliminary data from the P-I portion of the P-I/II (JBI-802-02) study of JBI-802 (oral dual LSD1/HDAC6 inhibitor) in pts with r/r or intolerant ET, PV & MDS/MPN with thrombocytosis, selected for an oral presentation at ASH 2026 As of Jun 30, 2026, all 8 pts on 15mg achieved >50% platelet… The post Jubilant Therapeutics Reports Preliminary P-I Data of JBI-802 for Essential Thrombocythemia and Related MPNs appeared first on PharmaShots.
News
Latest industry coverage
Google News
Nov 11, 2026, 12:58 PM
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine - Pharmaceutical Technology
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine  Pharmaceutical Technology
Google News
Nov 11, 2026, 12:56 PM
News Innovation in pharma not a prescription for boosting logistics profits - The Loadstar
News Innovation in pharma not a prescription for boosting logistics profits  The Loadstar
Google News
Nov 11, 2026, 12:23 PM
Build-a-biotech: Transitioning from academia to commercialization - BioXconomy
Build-a-biotech: Transitioning from academia to commercialization  BioXconomy
Google News
Nov 11, 2026, 12:11 PM
Drug licensing exports grow 54-fold in 10 years as China's biotech sector advances on research talent and cost competitiveness - https://economy.ac/
Drug licensing exports grow 54-fold in 10 years as China's biotech sector advances on research talent and cost competitiveness  https://economy.ac/
Google News
Nov 11, 2026, 11:53 AM
Baheal rebrands to Baheal Pharmaceutical as manufacturing drives 36% of profit - Dealroom
Baheal rebrands to Baheal Pharmaceutical as manufacturing drives 36% of profit  Dealroom
Google News
Nov 11, 2026, 11:50 AM
Sikkim Makes 5% of India’s Factory-Made Medicines. Almost All of It Moves on One Highway. - Logistics Insider
Sikkim Makes 5% of India’s Factory-Made Medicines. Almost All of It Moves on One Highway.  Logistics Insider
Google News
Nov 11, 2026, 11:45 AM
Announcing the Top 10 Leading Value-Creating Enterprises in Vietnam's Pharmaceutical and Medical Equipment Industry in 2026. - Vietnam.vn
Announcing the Top 10 Leading Value-Creating Enterprises in Vietnam's Pharmaceutical and Medical Equipment Industry in 2026.  Vietnam.vn
Google News
Nov 11, 2026, 11:34 AM
Analysis suggests US bid to increase German drug prices will increase costs for both - FirstWord Pharma
Analysis suggests US bid to increase German drug prices will increase costs for both  FirstWord Pharma
Google News
Nov 11, 2026, 11:20 AM
How government allows patients to be looted - Down To Earth
How government allows patients to be looted  Down To Earth
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer